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The Epstein-Barr virus (EBV) BamHI Q promoter (Qp) is the only promoter used for the transcription of
Epstein-Barr virus nuclear antigen 1 (EBNA-1) mRNA in cells in the most restricted (type I) latent infection
state. However, Qp is inactive in type III latency. With the use of the yeast one-hybrid system, a new cellular
gene has been identified that encodes proteins which bind to sequence in Qp. The deduced amino acid sequence
of the gene has significant homology to the interferon regulatory factors (IRFs). This new gene and products
including two splicing variants are designated IRF-7A, IRF-7B, and IRF-7C. The expression of IRF-7 is
predominantly in spleen, thymus, and peripheral blood leukocytes (PBL). IRF-7 proteins were identified in
primary PBL with specific antiserum against IRF-7B protein. IRF-7s can bind to interferon-stimulated response element (ISRE) sequence and repress transcriptional activation by both interferon and IRF-1. Additionally, a functional viral ISRE sequence, 5*-GCGAAAACGAAAGT-3*, has been identified in Qp. Finally, the
expression of IRF-7 is consistently high in type III latency cells and almost undetectable in type I latency,
corresponding to the activity of endogenous Qp in these latency states and the ability of the IRF-7 proteins to
repress Qp-reporter constructs. The identification of a functional viral ISRE and association of IRF-7 with type
III latency may be relevant to the mechanism of regulation of Qp.
terpart to human IRF-3 (2, 10, 12, 16, 17, 28, 29, 50, 52, 56).
Some IRFs are linked to IFN signal transduction; e.g., some of
the IRFs are induced or activated by IFN, and at least two
factors are involved in the regulation of an IFN gene (13, 14,
17, 22, 29, 50). However, IRFs have additional diverse functions, not necessarily linked to IFN, as regulators of cell growth
and differentiation (12, 18, 19, 30, 46–48). The hallmark of this
family is a conserved N-terminal DNA-binding domain with a
five-tryptophan repeat (10, 50). In common to IRFs is the
ability to bind to the core region of the IFN-stimulated response element (ISRE) found in the promoters of IFN-responsive genes.
The newly cloned gene and products including two splicing
variants are designated IRF-7A, IRF-7B, and IRF-7C. Assays
with reporter constructs raise the possibility that the IRF-7
proteins are implicated in IFN signal transduction at the transcriptional level. The discovery of IRF-7 has also led to the
identification of a functional viral ISRE sequence in Qp. Finally shown here is an association of IRF-7 expression with
type III latency in which IRF-7 expression is high. Since IRF-7
can repress Qp activity in reporter constructs, IRF-7 may contribute to rendering Qp inactive in type III latency.

The malignant diseases associated with Epstein-Barr virus
(EBV) are characterized by infection that is for the most part
latent. Several types of latency are classified based on the
pattern of viral protein expression. In a highly restricted form
called type I latency, only EBNA1, which is required for replication of the EBV episome, is expressed and only the BamHI
Q promoter (Qp) is active for transcription of EBNA1 mRNA.
However, in type III latency, EBNA1, EBNA2, EBNA3A,
EBNA3B, EBNA3C, LMP-1, LMP-2A, and LMP-2B are expressed. Interestingly, Qp is inactive in type III latency, and
another promoter is used for EBNA1 transcription (reviewed
in references 23 and 37).
Qp transcriptional activity is controlled by both viral and
cellular factors (5, 31, 39, 43, 44). A downstream element
appears to be the final control point for Qp transcription. The
sequence, the Q locus (see Fig. 5A), contains two binding sites
for the EBNA1 protein, which binds and acts in an autoregulatory manner to repress Qp transcription (39, 44). However,
E2F1 or an E2F-like molecule can displace the binding of
EBNA1 through adjacent binding sites within the Q locus and
overcome EBNA1-mediated repression of Qp (43).
An essential cis-acting element, whose mutation abolishes
the constitutive activity of the promoter, has been identified in
Qp (31, 44). Cloning of the products of cDNAs which can bind
to this specific sequence uncovered a new member of the
interferon (IFN) regulatory factor (IRF) family.
IRFs were first discovered through studies of regulation of
an IFN gene (29). The IRF family includes IRF-1, IRF-2,
IFN-stimulated gene factor 3g (ISGF-3g), IFN consensus sequence binding protein (ICSBP), human IRF-3, Pip/LSIRF/
ICSAT, and chicken IRF-3 (cIRF-3), which is not the coun-

MATERIALS AND METHODS
Cloning of IRF-7 with the use of the yeast one-hybrid system. Briefly, the
double-stranded oligonucleotide with the sequence 59-AGCTTTGCGAAAACG
AAAGTGCGTCGACGCTTTGCGAAAACGAAAGTGCGGTACCGCTT
TGCGAAAACGAAAGTGCT-39 was obtained by annealing two single-stranded oligonucleotides. The resulting oligonucleotide contains three copies of F7/8
sequence from EBV Qp and was subcloned into the XhoI site of pLR1-D1 (53)
as well as the EcoRI site of pHR307a (55). The yeast strain EGY48 (a gift of R.
Brent), harboring both plasmids, was transformed with DNA from the cDNA
library made from EBV-immortalized B cells (11). Yeast cells with His1 b-Gal1
phenotypes were selected. The cDNA plasmids from His1 b-Gal1 yeast colonies
were isolated; their ability to specifically activate 3xF7/8 sequences was confirmed by retransforming them into yeast. Then, two primers derived from the
library vector plasmid were made as described previously (11). Primer A (59-TA
ATACGACTCACTATAGGGAGACCACATGGATGAGTATATAACTATC

* Corresponding author. Mailing address: Lineberger Comprehensive Cancer Center, University of North Carolina, Campus Box 7295,
Chapel Hill, NC 27599. Phone: (919) 966-1183. Fax: (919) 966-3015.
E-mail: luzhang@med.unc.edu.
5748

VOL. 17, 1997
ATTTC-39) contains a T7 promoter sequence placed in an appropriate position
to allow the transcription of the cDNA insert by T7 RNA polymerase. Primer B
is 59-CTACCAGAATTCGGCATGCCGGTAGAGGTGTGGTCA-39. The
PCR product could then be directly added to a coupled transcription and translation system (TNT; Promega). The translation lysates were used in an electrophoretic mobility shift assay (EMSA) to test whether the protein generated could
bind directly to the F7/8 sequence. Two positive clones, c2a and c5a, which
encode proteins that can directly bind to the target sequence, were used for
further analysis.
Sequence analysis of IRF-7 cDNA. The cDNA inserts of c2a and c5a were
subcloned into the pBS1 vector at the BamHI site to generate pBS-c2a and
pBS-c5a, respectively. These two plasmids were subjected to nested deletional
exonuclease III treatment (38). The set of deletion constructs from each end of
the inserts were sequenced with M13 forward or M13 reverse primer. Both
strands of cDNA were sequenced largely by the University of North Carolina
sequencing facility with Taq DNA polymerase. For some ambiguous sequences,
Sequenase (U.S. Biochemical) and single-stranded DNA were used to verify the
sequences. A specific primer from clone c2a and primer B were used for PCR to
isolate further 59 upstream sequence of the clones. The resulting PCR products
from a human B-cell cDNA library were subcloned into the pBS1 vector. The
three longest clones were sequenced, and identical sequences from these three
clones were analyzed and deposited into GenBank.
Two Expressed Sequenced Tag (EST) database cDNA clones deposited by
I.M.A.G.E. Consortium (25) were obtained and sequenced the same way as the
c2a and c5a clones. The I.M.A.G.E. clone identification numbers for these clones
are 172449 and 153389.
Plasmid construction. Both the F7 oligonucleotide, 59-GATCGCTTTGCGA
AAACGAAAGTGC-39, and its complementary F8 oligonucleotide with a linker
sequence 59-GATC were annealed (F7/8) and subcloned into the BglII site of
pA10CAT (24). The plasmid containing multiple (four) insertions of the F7/8
fragment was named pA10-F7/8. The c5a and c2a cDNA inserts were subcloned
into the BamHI site of the pcDNA3 vector to generate the IRF-7A and IRF-7B
expression plasmids pcDNA–IRF-7A and pcDNA–IRF-7B, respectively. The
MscI-NotI fragment of clone 172449 was subcloned into pcDNA3 at the EcoRV
and NotI sites and named pcDNA-IRF-7C. The MscI-SmaI fragment of clone
172449 was subcloned into the EcoRV site of pcDNA3 and named pcDNA–
IRF-7C.1. pcDNA–IRF-7C.1 contains the complete open reading frame (ORF)
for IRF-7C, but lacks the 39 end of the clone containing the complete IRF-7C.2
ORF (see Fig. 1A). The IRF-1 cDNA fragment from SV-ISGF2 (35) was transferred into the pBS1 vector (pBS-IRF-1) for in vitro transcription and translation.
In vitro transcription and translation. The proteins were made with the TNT
coupled transcription and translation kit (Promega) essentially as specified by the
manufacturer. Plasmids pcDNA–IRF-7A, pcDNA–IRF-7B, pcDNA–IRF-7C,
and pcDNA–IRF-7C.1 were used for translation of IRF-7 proteins, and pBS–
IRF-1 was used for IRF-1.
Production and purification of antibody against IRF-7. The BglII fragment of
c2a (IRF-7B) was subcloned into the BamHI site of the pET-28a (1) vector
(Novagen). The protein was expressed in the Escherichia coli host BL21(DE3)
with a polyhistidine tag at the N terminus. Protein expression was induced by
treatment with 0.8 mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 4 h. E.
coli was pelleted and prepared for purification under denaturing conditions with
Ni-nitrilotriacetic acid resin as specified by the manufacturer (Qiagen). The
purified protein was sent to Cocalico Biological, Inc., for antibody production in
a rabbit. The antiserum was diluted 1:10 and used for EMSA. However, for
Western blot analysis, the antiserum was affinity purified by a standard method
(38).
Northern blot analysis. The multiple-human-tissue mRNA blot was purchased
from Clontech. The IRF-7A (c5a) fragment was labeled with [a-32P]dATP and
[a-32P]dCTP by random priming with Klenow enzyme (38). The subsequent
hybridization and washing were done as recommended by the manufacturer.
PBL. The fresh peripheral blood leukocytes (PBL) from healthy donors were
gifts from S. Haskill, UNC-Lineberger Comprehensive Cancer Center.
Western Blot analysis with enhanced chemiluminescence. Separation of proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed standard methods. After the proteins were transferred to a nitrocellulose or Immobilon membrane, the membrane was blocked with 5% nonfat dry
milk in TBST (50 mM Tris [pH 7.5], 200 mM NaCl, 0.05% Tween 20) at room
temperature for 10 min. It was then washed briefly with water and incubated with
the first antibody in 5% milk in TBST for 1 h at room temperature or overnight
at 4°C. After being washed with TBST three times (10 min each), the membrane
was incubated with the secondary antibody at room temperature for 1 h. It was
then washed three times with TBST as before, treated with enhanced chemiluminescence detection reagents (Amersham), and exposed to Kodak XAR-5
film.
EMSA. The DNA probes were generated by annealing oligonucleotides and
filling in any single-stranded overhang with Klenow enzyme. EMSA was performed essentially as described previously (26). In vitro-translated reticulate
lysates (5 ml) were incubated for 20 min at room temperature with 20,000 to
50,000 cpm of labeled probe in a volume of 12.5 ml containing 20 mM HEPES
(pH 7.9), 1 mM MgCl2, 0.1 mM EGTA, 0.5 mM dithiothreitol, 320 mg of
poly(dI-dC)-poly(dI-dC), and 4% Ficoll-400. The samples were separated on a
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preelectrophoresed 4.8% polyacrylamide gel in 20 mM Tris-borate-EDTA
(TBE) buffer. After electrophoresis, the gels were dried and subjected to autoradiography. The conditions for the competition assay between IRF-1 and
IRF-7s were essentially the same, except that less probe was used (3,000 to 4,000
cpm). When antiserum was needed, 1 ml was added to the reaction mixture. The
consensus ISRE oligonucleotide was synthesized as specified in a previous report
(22). AP-1 and SP-1 competitors were purchased from Promega.
Cell culture, transient transfection, and CAT assay. DG75 is an EBV-negative
Burkitt’s lymphoma cell line (3); Sav I and Sav III, and Kem I and Kem III are
paired EBV-positive Burkitt’s lymphoma cell lines that differ only in their latent
infection state (gifts from J. Sample [32]). All cells were maintained in RPMI
1640 plus 10% fetal bovine serum. Electroporation was used for transfection as
described previously (43). IFNs were added at a final concentration of 500 IU/ml
about 30 min after transfection. Cell lysates were prepared after 36 to 48 h. The
chloramphenicol acetyltransferase (CAT) assays were performed by standard
methods (15) and analyzed on a Molecular Dynamics PhosphorImager. The
results represented an average of at least three independent transfections; two
batches of plasmid preparations were used.
Nucleotide sequence accession numbers. The nucleotide sequence data reported in this paper have been submitted to GenBank under accession no.
U53830 to U53832.

RESULTS
Cloning of IRF-7 by the yeast one-hybrid system. A cisacting region needed for constitutive activity of Qp was localized to a 21-bp sequence through its protein-binding activity
(F7/8, nucleotides [nt] 62399 to 62419 of EBV B95-8 [see Fig.
5A]). A point mutation in this region abolished both specific
DNA-binding and promoter activity (44). The F7/8 sequence
(three insertions) was used in a yeast one-hybrid system, similar to that previously published (20, 51) (see Materials and
Methods), to identify any cellular protein(s) that bound to the
F7/8 sequence. Two positive cDNA clones, c2a and c5a, were
selected for sequencing analysis because they encoded proteins
that could bind to the target sequence (F7/8) directly in EMSA
(data not shown). The two clones have identical sequences,
except that c5a is 87 nt longer than c2a. The c2a clone is
apparently a splicing variant of c5a and lacks 29 amino acids
(aa) in its ORF (Fig. 1A and B; the c5a and c2a products have
been renamed IRF-7A and IRF-7B, as explained below). Since
the 59 upstream sequence of both clones did not contain an
in-frame stop codon, PCR was used to isolate further 59 upstream sequence of the cDNAs, which disclosed an in-frame
stop codon. Thus, translational initiation codons were positively identified for both the c2a and c5a clones. A database
search with the final deduced amino acid sequence revealed
that these two cDNAs encode novel proteins most closely
related to the IRF family. Both clones showed 29 to 52%
identity to various members of the IRFs in their conserved
N-terminal DNA-binding domain (Fig. 1C). The IRF member
with highest homology to our clone is cIRF-3. The c5a clone
and cIRF-3 have 42% overall identity and 52% identity in the
N-terminal regions. This new gene and its products are designated IRF-7A (c5a clone) and IRF-7B (c2a clone). A database
search with the nucleotide sequence showed that the 39 end of
the cDNA matched the sequences of two clones in the EST
database (98% identity in a ca. 300-nt region). Sequence analysis disclosed that these two clones are identical in their 39-end
sequence; however, one of them does not have a complete
59-end sequence. Both EST clones also appear to be a splicing
variant of IRF-7A and lack 227 nt in the middle of the cDNA.
This splicing actually changes the original reading frame so
that a smaller protein (164 aa) may be generated, which is
designated IRF-7C (Fig. 1A and B).
There are two cryptic ORFs in both IRF-7A and IRF-7B
cDNAs that are absent in IRF-7C cDNA. These ORFs are in
an alternative reading frame from IRF-7A and IRF-7B. The
additional ORF in IRF-7A cDNA has 200 aa, and the cryptic
ORF in IRF-7B cDNA has 171 aa because 29 aa in the middle
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FIG. 1. cDNA and protein structures of IRF-7s. (A) The ORFs are represented by open and solid bars. The open bars represent the ORFs confirmed as encoding
proteins. IRF-7C has a 13-aa sequence difference from IRF-7A in its C terminus (Fig. 1B), indicated by the shaded bar. The solid bars indicate the unconfirmed ORFs.
The lengths of cDNAs (in kilobases) are shown in parentheses. (B) The primary sequence of IRF-7s deduced from the nucleotide sequence of cDNAs. The deduced
amino acid sequence of IRF-7A is shown. The underlined sequence is that missing in IRF-7B. The first 151-aa sequence of IRF-7C is identical to that of IRF-7A and
IRF-7B. The last 13 aa of IRF-7C are different and are shown in italics. The sequence homology between the 13 aa of IRF-7C and of IRF-7A and IRF-7B is also shown.
(C) Alignment of the N-terminal region of IRF-7 with other members of the IRF family. Gaps have been introduced to allow the best alignment. The conserved
tryptophans are indicated by asterisks.
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FIG. 2. Expression of IRF-7 mRNA in various human tissues. Lanes 1 to 8
contain 2 mg of mRNA each from spleen, thymus, prostate, testes, uterus, small
intestine, colon (mucosal lining), and PBL, respectively, which had been separated and blotted (Clontech). The blot was examined by Northern analysis with
labeled IRF-7A cDNA as a probe. The positions of RNA standards (in kilobases)
are indicated on the left. The positive signals, with sizes, are indicated by arrows
on the right. The bottom panel indicates the level of actin mRNA as control.

is missed due to splicing. A sequence homology search disclosed that these hypothetical proteins have low homology
(24% identity) to human type II collagen protein in a 120-aa
region (6). Since some proteins can be translated from different ORFs within the same mRNA (36), these hypothetical
proteins are designated collagen homolog protein a (CHP-a)
and CHP-b, respectively (Fig. 1A).
IRF-7C cDNA also contains an additional ORF, located in
the 39 end of the cDNA; its amino acid sequence is identical to
aa 294 to 503 of IRF-7A, presuming that the methionine codon
at aa 294 (of IRF-7A) could be used as a translational initiation codon (Fig. 1A). This hypothetical protein was designated
IRF-7C.2. A region in IRF-7C.2, which is also present in
IRF-7A and IRF-7B, has some homology to the interaction
domain of ISGF-3g with Stat1 and Stat2 (50). Whether CHPs
and IRF-7C.2 can be translated from their mRNAs is unknown.
With labelled IRF-7A cDNA as the probe, human genomic
DNA from both DG75 and HeLa cells digested by BamHI or
HindIII disclosed a single predominant band in Southern blot
analysis (data not shown). The results suggest that the human
genome contains only one copy of the IRF-7 gene. Therefore,
IRF-7B and IRF-7C are most likely to be splicing variants of
IRF-7A rather than being derived from different genes.
Tissue distribution of IRF-7 mRNA. Northern analysis of a
blot of multiple human tissue mRNAs (Clontech) with labeled
IRF-7A cDNA as a probe showed that IRF-7 mRNAs are
expressed predominately in spleen, thymus, and PBL (Fig. 2,
lanes 1, 2, and 8). However, almost all the other tissues examined showed a low level of expression. There were two major
bands, of 2 and 2.6 kb respectively, that hybridized to IRF-7A
probe. Interestingly, the 2.6-kb band appeared strong in both
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spleen and thymus; however, it was weak in PBL (compare
lanes 1 and 2 with lane 8). The identity and significance of
these bands are unknown, and it is hard to distinguish the
various mRNAs of IRF-7. However, the 2-kb mRNA should
contain at least some IRF-7A mRNA since IRF-7A is the
major form of IRF-7 proteins identified in PBL (Fig. 3A).
Besides the two major bands, an additional weak band of 5.1
kb appeared in every tissue examined. This might be an additional splicing variant, an unprocessed RNA, or a nonspecific
band.
Identification of IRF-7 protein in primary cells. To confirm
that the cDNA clones actually encode the predicted proteins,
cDNA fragments were cloned into an expression vector,
pcDNA3. Antibody against IRF-7 was generated by inoculating purified full-length IRF-7B protein into rabbits (see Materials and Methods). The antiserum was affinity purified before being subjected to Western blot analysis (38). The results
in Fig. 3 clearly show that IRF-7s are expressed and identified
from these cDNAs in cells (lanes 1 to 4). The sizes of the
proteins detected (69, 67, and 23 kDa for IRF-7A, IRF-7B, and
IRF-7C, respectively) were close to the predicted sizes and also
matched the sizes of the in vitro-translated proteins (data not
shown). From the tissue distribution of mRNA by Northern
blot analysis (Fig. 2), the IRF-7 gene should be expressed in
PBLs. Six normal PBLs (three of them are shown) obtained
from healthy donors disclosed the presence of IRF-7A protein
(Fig. 3A, lanes 5 to 7). However, the expression of IRF-7B and
IRF-7C is uncertain. A weak band corresponding to the plasmid-expressed IRF-7B and IRF-7C can be detected (data not

FIG. 3. Identification of IRF-7 proteins in primary PBL. (A) Protein samples
were separated by SDS–8% PAGE and subjected to Western blot analysis with
antibody against IRF-7B. Lanes: 1 to 4, DG75 cells transfected by pcDNA3 (lane
1), pcDNA-IRF-7A (lane 2), pcDNA-IRF-7B (lane 3), and pcDNA-IRF-7C
(lane 4); 5 to 7, PBLs from three normal healthy donors. The molecular mass
standards (Rainbow markers; Amersham) are indicated on the left in kilodaltons. (B) Conditions are identical to those in panel A, except that SDS–12%
PAGE was used to identify IRF-7C. Lanes 1 to 4 are the same as in panel A.
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FIG. 4. IRF-7s are DNA-binding proteins. The probe was F7/8 labelled with [a-32P]dCTP. Cold competitors were all added at a 100-fold molar excess over hot
probe (F7/8). The lanes labeled preimmune and immune contain preimmune and immune sera for intact IRF-7B protein. Lanes: 1, free probe; 2 to 5, reticulocyte lysates
containing in vitro-translated proteins from plasmids pcDNA3, pcDNA-IRF-7A, pcDNA–IRF-7B, pcDNA–IRF-7C, respectively, used for EMSA; 6 to 14, reticulocyte
lysate containing in vitro-translated protein from pcDNA3–IRF-7C.1. F7/8 and ISRE sequence from ISG15 were used as cold competitors in lanes 8 and 9, and AP-1
and SP-1 were used in lanes 10 and 11. Preimmune serum was used in lane 12, and immune serum was used in lane 13. Nonrelevant rabbit polyclonal antibody against
DP-1 (Santa Cruz) was used in lane 14. The arrows denote IRF-7-specific bands.

shown). Apparently, IRF-7A is the predominant form in PBL.
Several fast-migrating proteins are generated with IRF-7A and
IRF-7B expression constructs (lanes 2 and 3). These forms
possibly originate from the usage of internal methionine
codons for translational initiation. Other explanations include additional splicing of mRNA and proteolytic processing of the intact proteins. Interestingly, PBLs, which have
strong expression of IRF-7A, did not show these additional
bands.
IRF-7 proteins are DNA-binding proteins. The results of the
yeast one-hybrid screening indicated that IRF-7 could bind to
DNA in vivo. EMSA was then used to test the DNA-binding
properties of intact IRF-7 in vitro. IRF-7s were translated in
vitro, and their expression was confirmed by Western blot
analysis (data not shown). These lysates were used for EMSA.
As shown in Fig. 4, specific bands appeared when IRF-7s were
used for EMSA (lanes 3 to 6). These bands were specific for
the following reasons. (i) They disappeared in the presence of
an excess of cold competitors, such as F7/8 and consensus
ISRE from the IFN-stimulated gene 15 (ISG 15) promoter
(Fig. 4, lanes 8 and 9), but nonspecific competitors, such as
AP-1 and SP-1, had no effect (lanes 10 and 11). The consensus
ISRE was used as a competitor because a similar element was
found in F7/8 and subsequently proven to function as an ISRE
(see below and Fig. 5 for details). (ii) DNA-binding activity was
not affected when preimmune serum and nonrelevant antibody
(anti-DP-1) were used (Fig. 4, lanes 12 and 14); however,
specific IRF-7 antibody could supershift the IRF-7C–DNA
complex (lanes 13). The DNA-binding activity of IRF-7A and

IRF-7B proteins was also specific (data not shown). Essentially
identical results were obtained with consensus ISRE sequence
from ISG 15 as a probe (data not shown). Thus, these forms of
IRF-7s are DNA-binding proteins that bind specifically to
ISRE sequence both in vivo (yeast one-hybrid) and in vitro
(EMSA). Furthermore, IRF-7C, which has only 164 aa, can
bind to the ISRE sequence, indicating that the DNA-binding
domain of IRF-7, similar to other IRFs, is localized in the
N-terminal region (Fig. 1A).
EBV Qp has a functional ISRE site. After the cloning of
IRF-7, an ISRE sequence was identified in Qp: 59-GCGAAA
ACGAAAGT-39 (nt 62404-62417 of the EBV B95-8 strain
[Fig. 5A]). This is identical to the consensus ISRE sequence,
59-(A/G)NGAAANNGAAACT-39 (8), except at the underlined position, where the conserved C is replaced by a G in Qp.
The same C-to-G replacement has been found in the ISRE of
the promoter of guanylate-binding protein (9). The obvious
functional experiment was to test whether Qp can be activated
upon IFN treatment. However, the full-length Qp reporter
construct did not respond to IFN-a, IFN-b, or IFN-g treatment (data not shown). This result might be due to negative
regulatory elements in the promoter or the cell lines tested.
Next, four copies of F7/8, which contains the putative ISRE
sequence, were placed in front of an enhancerless promoterreporter construct, pA10CAT. The resulting construct, pA10F7/8 (Fig. 5A), was introduced into DG75 cells by electroporation. Both IFN-a and IFN-b could transactivate the reporter
construct eightfold (Fig. 5B, lanes 4 and 5). However, IFN-g
had a limited effect (lane 6). Based on the responsiveness to
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FIG. 5. Stimulation of an element in Qp by IFN. (A) Schematic representation of Qp promoter constructs used in transient-transfection assays (modified from
reference 43). The RNA start site for Qp is indicated by an arrow (41). The F7/8 sequence, ISRE (open square), and its relative coordinates to the Qp start site, as
well as promoter constructs used for Fig. 6C, are shown. The Q-locus (solid ovals) and E2F1-binding sites (lines) are also shown. (B) EBV Qp contains an ISRE. DG75
cells were transfected with pA10CAT or pA10-F7/8. The transfected cells were divided equally into two wells of a six-well plate, and IFN-a, IFN-b, or IFN-g was added
in one well. Cell lysates were used for the CAT assay by standard procedures and analyzed on a Molecular Dynamics PhosphorImager. The results are expressed as
fold activation upon IFN treatment. The final concentration of all IFNs was 500 IU/ml. Standard error bars are shown.

both IFN-a and IFN-b, as well as the sequence similarity to
consensus ISRE, we concluded that Qp has a functional ISRE
sequence.
Expression of IRF-7 is associated with EBV latency. Sav I
and Sav III, as well as Kem I and Kem III, are sister Burkitt’s
lymphoma lines, each derived from a single parental cell line.
The paired lines differ only in their types of latency. Whether
IRF-7 is associated with EBV latency was tested by Western
blot analysis with IRF-7 antibody. As shown in Fig. 6B, IRF-7A
is expressed at a much higher level in type III cells (Fig. 6B,
lanes 2 and 4) than in type I cells (lanes 1 and 3). However, the
IRF-1 levels were essentially the same in the type I and III cells
(data not shown). Latency types were confirmed by detection
of EBNA1, EBNA2, and LMP1 proteins by Western blot analysis with specific antibodies (data not shown). IRF-7A was also
expressed at a higher level in SFC-4 and CB95 cells, which are
type III (33), than in Akata type I cells (reference 45 and data
not shown). Therefore, without exception, in all the cell lines
tested, the expression of IRF-7 is greater in type III than in
type I latency.
IRF-7 proteins can repress the activity of Qp reporter constructs. The function of IRF-7 in the regulation of Qp was
studied in cotransfection experiments with DG75 cells, chosen
because these cells contain trace amounts of endogenous
IRF-7s (Fig. 3, lanes 1). Cotransfection of IRF-7-expression
plasmids with pF1-CAT, a Qp reporter construct containing
the ISRE sequence (43) (Fig. 5A), resulted in decreases in the
basal activity of Qp (Fig. 6C, lanes 2 to 5). However, IRF-1 can
activate this reporter construct (less than twofold [data not
shown]), confirming a recent report (40). A similar result was
obtained when pF3-CAT (Fig. 5A), another Qp reporter construct containing ISRE sequence, was used for this experiment
(data not shown). At the same time, different IRF-7 expression
plasmids were cotransfected with pF2x-CAT (Fig. 5A), which
does not contain the ISRE sequence, or cotransfected with a
Rous sarcoma virus CAT construct into DG75 cells. IRF-7s
repressed neither pF2x-CAT nor a Rous sarcoma virus reporter construct (data not shown), indicating that the repression of Qp by IRF-7s is specific. Thus, three forms of IRF-7
repressed Qp activity by 45 to 70%.

IRF-7 proteins repress IFN-a-activated reporters through the
ISRE. Since some IRFs are regulators of IFN signal transduction, the effect of IRF-7 on the activation of promoter constructs by IFN was tested. The three forms of IRF-7 (A, B, and
C) could significantly reduce IFN-a-induced activation of the
Qp ISRE construct (Fig. 7A, lanes 2 to 4). Activation by IFN-a
of another reporter construct, 15K ISRE(1), with a single copy
of the ISRE sequence from the cellular ISG 15 promoter
placed in front of human immunodeficiency virus (HIV) long
terminal repeat promoter sequence (HIV-CAT) (35), could
also be repressed (Fig. 7B). The vector constructs, HIVCAT and pA10CAT, could not be activated by IFN-a (data
not shown). Therefore, the activation by IFN-a and subsequent repression by IRF-7s must be through the ISRE sequence.
IRF-7 proteins repress transactivation by IRF-1 through the
ISRE. Since IRF-2, ICSAT, and ICSBP can inhibit the activation of certain reporter constructs by IRF-1, we tested whether
IRF-7 could inhibit IRF-1-induced transactivation. Cotransfection of IRF-1 and 15 K ISRE(4), which has four copies of
ISRE sequence from the ISG15 promoter in front of the HIV
minimal promoter (35), led to about a ninefold activation (Fig.
8, lanes 1 and 2). However, with coexpression of IRF-7s, activation of the reporter gene by IRF-1 was reduced significantly
(lanes 3 to 6), similar to the inhibitory effect of IRF-2, which is
a known repressor of IRF-1 (lane 7). Therefore, IRF-7s can
repress transactivation by IRF-1. The vector construct, HIVCAT, could not be activated by IRF-1 (data not shown).
Hence, the activation by IRF1 and subsequent repression by
IRF-7s must be through the ISRE sequence.
IRF-7 proteins can compete with IRF-1 for the ISRE site.
Since IRF-1 and IRF-7s all can bind to ISRE sequence, the
different factors may compete for binding to ISRE and provide
the mechanism through which IRF-7s repress transactivation
by IRF-1. As a general test of such a possibility, graded
amounts of in vitro-translated IRF-7A or IRF-7C lysates were
mixed with a fixed amount of in vitro-translated IRF-1, and
EMSA was performed. The binding of IRF-1 to ISRE sequence gradually decreased as the amount of IRF-7 was increased (Fig. 9A, lanes 5 to 7; Fig. 9B, lanes 6 to 8). Non-
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FIG. 6. Correlation between expression of IRF-7, type of latency, and repression of Qp. (A) Schematic diagram of Qp status and EBV latency. (B)
IRF-7A is associated with type III latency. Equal amounts of protein lysates were
electrophoresed by SDS–10% PAGE and stained with Ponceau S Red after
transfer of protein to the membrane. Western blot analysis with IRF-7 antibody
was performed. The identity of IRF-7A was determined by comparison with
plasmid-expressed IRF-7A and IRF-7B. Lanes: 1 to 4, cell lysates from Sav I, Sav
III, Kem I, and Kem III, respectively. The molecular mass standards (Rainbow
markers) are indicated on the left in kilodaltons. (C) Repression of Qp activity
by IRF-7s. DG75 cells were transfected with pF1-CAT reporter construct and
pcDNA3, pcDNA–IRF-7A, pcDNA–IRF-7B, pcDNA–IRF-7C, and pcDNA–
IRF-7C.1. Cell lysates were used for the CAT assays. The results are expressed as CAT activity relative to the vector control. Standard error bars are
shown.

relevant protein, the in vitro-translated EBV BZLF-1
protein, did not produce such an effect (Fig. 9A, lane 8; Fig.
9B, lane 9). Therefore, both IRF-7A and IRF-7C can compete with IRF-1 for binding to ISRE. IRF-7B was not tested
because it migrates close to IRF-1 in EMSA (data not shown).
DISCUSSION
IRF-7 and EBV latency. Our data strongly point to the relevance of IRF-7 as a repressor of Qp in type III latency: (i) the
expression of IRF-7 is consistently high in type III cells, where

MOL. CELL. BIOL.

Qp is inactive, and low in type I cells, where Qp is active (Fig.
6A and B); (ii) overexpression of IRF-7 can repress the constitutive activity of Qp-reporter constructs (Fig. 6C); (iii)
IRF-7 was isolated through a yeast one-hybrid system with the
Qp ISRE sequence as bait, indicating IRF-7 can bind to Qp in
vivo; and (iv) in vitro-translated IRF-7s can bind to Qp, as
shown by EMSA with Qp ISRE as a probe (Fig. 4).
Qp is obviously carefully regulated. Autorepression by its
viral product, EBNA-1, and release of this repression by E2F
are unique features of Qp regulation (39, 43, 44). However,
perhaps the most intriguing aspect of Qp is how it is rendered
inactive selectively. Selective control of the promoter appears
to be cellularly based. The data in this paper suggest that
IRF-7 may act as a repressor but that its availability depends
on the latency cell type, namely, type III. Inactivation of
Qp might be the result of composite effects of IRF-7 and
possibly other IRFs, as well as other repressors, such as
EBNA1.
It is interesting that Qp has a functional ISRE, which suggests that other IRFs may also have the potential to bind to
and provide Qp with a spectrum of regulatory possibilities.
This idea is supported by a recent report that IRF-1 and IRF-2
are responsible for the constitutive activity of Qp (40), as well
as our own data that IRF-1 can activate and IRF-7s can repress
Qp activity.
Furthermore, EBNA2 (expressed in type III but not type I
latency) has an anti-IFN effect. Burkitt’s lymphoma cells expressing EBNA2 protein can override the antiproliferative effect of IFN and reduce or abolish the expression of IFNstimulated genes (1, 21). The resistance of type III cells to the
antiproliferative effect of IFN may be related to high levels of
IRF-7 expression in such cells (1, 21), since IRF-7 is a negative
regulator of IFN and IRF-1 responsiveness. However, this
point must be vigorously tested.
Finally, the presence of a functional ISRE in Qp suggests
that Qp can be activated by IFN; however, IFN does not
activate intact Qp in CAT assays and in latently infected cells
(reference 40 and data not shown). Two possible explanations
for this result are that (i) EBNA1 can repress Qp activity
(autoregulation), making the activation of Qp undetectable,
and (ii) EBNA2 has an anti-IFN effect, making the activation
of Qp in type III cells by IFN more difficult. The best time to
detect Qp activation by IFN might be in primary infection,
where EBNA1 and EBNA2 are synthesized at much lower
levels. We are working on EBV infection of primary B cells to
see if IFN can activate Qp.
Structure and function of IRF-7. The tissue distribution of
IRF-7 mRNA suggests that tissue-specific splicing is occurring.
IRF-7 is expressed predominantly in lymphoid tissues. However, there are two major bands in the spleen and thymus (2.6
and 2 kb) and only one in PBL (2 kb) (Fig. 2). IRF-7C is
somewhat reminiscent of processed IRF-2 (7, 34). After viral
infection, IRF-2 can be processed by a proteolysis, resulting in
an approximately 160-aa N-terminal peptide which can also
bind to DNA. The ability of processed IRF-2 to function as a
repressor is significantly less than that of intact IRF-2 (34).
However, other studies show that the truncated versions of
IRF-2 repress reporter genes more efficiently than full-length
IRF-2 does (27, 54). Since IRF-2 is a negative regulator and an
antagonist to IRF-1, processing of IRF-2 is thought to be
involved in the IFN-regulated genes in which the ratio of
IRF-1 to IRF-2 can affect the level of transcription. IRF-7C,
which is close in size (164 aa) to the truncated version of IRF-2
(;160 aa), is generated through splicing rather than proteolytic digestion.
The sequence homology of IRF-7 to other IRFs suggests
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FIG. 7. Overexpression of IRF-7s inhibits IFN-a-induced activation. The experiments were done essentially as described in the legend to Fig. 5. The results are
expressed as fold activation upon treatment with IFN-a (500 IU/ml). (A) pA10-F7/F8 was cotransfected with pcDNA3 vector, pcDNA–IRF-7A, pcDNA–IRF-7B,
pcDNA–IRF-7C, or pcDNA–IRF-7C.1. (B) Conditions are identical to those for panel A, except that the reporter construct 15K ISRE(1) was used. Standard error
bars are shown.

that IRF-7 might function in the regulation of IFN stimulation.
The evidence in favor of such a role is strong. First, the expression of IRF-7s inhibits the IFN-activated ISRE reporter
constructs, including the newly identified ISRE from EBV Qp,
as well as an ISRE from a well-studied cellular promoter,
ISG15. Second, IRF-7s can negatively regulate transactivation
of IRF-1 through an ISRE. Since ISRE is a highly conserved
sequence and is present in the promoters of almost all IFNregulated early genes, it is tempting to speculate that IRF-7s
may be general regulators of IFN-regulated genes.
The structure of IRF-7C suggests that it might be a dominant negative regulator for IRF-7A and IRF-7B (Fig. 1A).
However, all three IRF-7s act as negative regulators of IFN
responses and transactivation by IRF-1, although the degree
of repression differs. As with other IRFs, IRF-7 may have its
own specific cellular function(s) and IRF-7C might be a
dominant negative regulator for IRF-7A and IRF-7B in the
function(s) related to the C-terminal region of the molecule
(Fig. 1A).
Since the pcDNA–IRF-7C.1 expression plasmid, which contains only the IRF-7C ORF and lacks the CHPs and IRF-7C.2
ORFs (Fig. 1A), has an effect similar to IRF-7A, IRF-7B, and
IRF-7C in regulating IFN responses and Qp, CHPs and IRF7C.2 are most probably not involved in the regulation of IFN
responses and Qp.
Knowledge of the mechanism of repression by IRF-7 is limited, except that IRF-7s can compete with IRF-1 for binding to
the ISRE sequence in vitro (Fig. 9); however, it is still not clear
how effectively IRF-7 can compete with IRF-1 in vivo. It also
quite possible that IRF-7 is able to interact with and neutralize
an activator, such as IRF-1 and/or ISGF3. The C-terminal
regions of IRF-7A and IRF-7B have some homology to the
interaction domain of ISGF-3g with Stat1 and Stat2 (49),
which makes an interaction between Stat1 and Stat2 (components of the ISGF3 complex) and IRF-7 plausible. It has also

been reported that members of the IRF family can interact
with each other (4, 42).
So far, several members of the IRF family are known to be
negative regulators of IFN-regulated genes, including IRF-2,
ICSBP, and Pip/LSIRF/ICSAT, to which may be added the
newly identified IRF-7. These apparently redundant negative

FIG. 8. Overexpression of IRF-7s inhibits transactivation by IRF-1. DG75
cells were transfected with the reporter construct 15K ISRE(4), and IRF-1, as
well as IRF-7 expression plasmids. Lanes: 1, pcDNA-3 vector alone; 2 to 7,
SV–ISGF-2, the IRF-1 expression plasmid, plus pcDNA3 vector, pcDNA–IRF7A, pcDNA–IRF-7B, pcDNA–IRF-7C, pcDNA–IRF-7C.1, or pcDNA–IRF-2,
respectively, were cotransfected. CAT assay results are expressed as CAT activity
relative to the vector control. Standard error bars are shown.
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FIG. 9. IRF-7 can compete with IRF-1 for the consensus ISRE site. 32P-labeled cellular ISG 15 ISRE probe and reticulocyte lysates containing in vitro-translated
proteins from various plasmids were used for EMSA analysis. (A) In vitro-translated IRF-7A was used. Lanes: 1, free probe. 2 and 3, 8 ml of reticulocyte lysates
translated from vector plasmid pBS1 (for IRF-1) and pcDNA3 (for IRF-7A), respectively; 4 to 7, 2 ml of lysates containing IRF-1 together with 0, 0.5, 2.5, and 6 ml
of lysates containing IRF-7A, respectively (the total volume of lysates was made up to 8 ml with a lysate of pcDNA3); 8, 2 ml of lysates from pBS1 and 6 ml from IRF-7C;
9, 4 ml of lysates containing IRF-1 plus 6 ml of in vitro-translated EBV BZLF-1. (B) In vitro-translated IRF-7C was used. Lanes: 1, free probe; 2 to 4, 7 ml of reticulocyte
lysates translated from no DNA, vector plasmid pBS1, and pcDNA3, respectively; 5 to 8, 4 ml of lysates containing IRF-1 together with 0, 0.5, 1.5, and 3 ml of lysates
containing IRF-7C, respectively (the total volume of lysates was made up to 7 ml with a lysate of pcDNA3); 9, 4 ml of IRF-1 plus 3 ml of in vitro-translated EBV BZLF-1;
10, 4 ml of lysates from pBS1 and 3 ml from IRF-7C.

regulators suggest a complex network of the IFN-regulated
genes. Further work is needed to reveal the functional significance of those common attributes. However, these factors
may have distinctive cellular functions not necessary linked to
IFN; e.g., Pip/LSIRF is able to interact with PU.1 and facilitate
the binding of Pip/LSIRF to the enhancer of the immunoglobulin light-chain gene, converting it to a transcriptional activator
(12).
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